|
NICE issues second draft guidance on Pixuvri for treatment of aggressive non …
pharmabiz.com The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have … |
|
You Shouldn’t Ignore Gilead’s Idelalisib
Motley Fool In early September, Gilead filed a new drug application with the Food and Drug Administration for idelalisib as a treatment for iNHL patients who fail to respond to treatment from current go-to drug rituximab — marketed as Rituxan by Biogen Idec … |
|
Thyroid Meeting Spotlights Dx, Tx of Cancer
MedPage Today “Although this result is disappointing, it is a very important finding since there is so much need for an effective therapy, and rituximab has been associated with so much hope,” Koenig said. A different small-molecule drug, however, has shown some … |
|
BioInvent, Bayer to extend development of therapeutic antibodies
Pharmaceutical Business Review BioInvent’s n-CoDeR libraries include over 20 billion (2 x 1010) highly diverse, fully human antibody fragments which have been created using the company’s patented approach, generating antibodies with high affinity and selectivity. BioInvent CEO … |
|
Special News: Gilead Sciences, Inc.(NASDAQ:GILD), Alcoa Inc (NYSE:AA)
SBWire (press release) It demonstrated “highly statistically significant efficacy” in patients receiving the treatment receiving idelalisib plus rituximab compared with those receiving rituximab alone, the company said. Are investors worried about the recent updates with … |
New therapeutic target for B-cell lymphomaDoctor TipsterStandard chemotherapy, called R-CHOP, consists of a combination therapy that includes a monoclonal antibody, a steroid and three other drugs ( rituximab , cyclophosphamide, doxorubicin, vincristin…
Drug Discovery & Development |
BioInvent, Bayer Extend Therapeutic Antibodies Collaboration
Drug Discovery & Development BioInvent International AB announced that it has signed an extension to its 2008 license agreement with Bayer Pharma AG for the development of antibodies from BioInvent’s n-CoDeR libraries. Under the terms of the extension, Bayer will broaden its … BioInvent and Bayer extend and broaden collaboration for the discovery and …HispanicBusiness.com |
|
Volume Alert: Gilead Sciences, Inc. (NASDAQ:GILD), NPS Pharmaceuticals, Inc …
Market News Call It demonstrated “highly statistically significant efficacy” in patients receiving the treatment receiving idelalisib plus rituximab compared with those receiving rituximab alone, the company said. Is GILD A Strong At The GALE? Get Advantage Of Our Free … |
Trial Updates and Public Offering – Research Report on Gilead, Celgene, Ariad …PR Newswire (press release)Gilead reported that the safety profile of idelalisib was acceptable and consistent with prior experience in combination with rituximab in previ…
|
BioInvent extends license agreement with Bayer to develop antibodies
News-Medical.net BioInvent International AB (OMXS: BINV) today announces that it has signed an extension to its 2008 license agreement with Bayer Pharma AG for the development of antibodies from BioInvent’s n-CoDeR® libraries. Under the terms of the extension, Bayer … BioInvent and Bayer extend and broaden collaboration for the discovery and …EON: Enhanced Online News (press release) |